'Stop it at the start, it's late for medicine to be nature, retrospective and often refer to patterns of drug usage that no longer hold, such as the use of prepared when disease has grown strong through delays' Ovid, in Remedia Amoris, about 10 bc.
short acting CCAs for hypertension, which is no longer common practice. Given all these caveats, it Ever since Ovid, the correct philosophy has been to is no surprise that case control studies do not prostop a disease in its early stages, so that antihypervide as strong evidence as other methods of study tensives are commonly started on the basis of elevsuch as cohort studies (somewhat stronger) or ranated blood pressure (BP) readings, using a variety of domized controlled trials (RCTs; much stronger agents, rather than waiting for end-organ damage to evidence). Nonetheless, case control studies cannot develop. Calcium antagonists, also called calcium be ignored at a time when every morsel of available channel blockers (CCBs) or calcium channel antagevidence needs careful assessment, and when the onists (CCAs), were once the darling of the hypernumber of outcome RCTs with CCAs is strictly limtension fraternity, yet are now under scrutiny. The ited. 'complaint' is chiefly based on three reports, each
The case control study of Psaty et al 1 concluded using a different technique: case control, 1 cohort, 2 that 'the use of short-acting calcium channel blockor meta-analysis.
3 Each has given rise to debate and ers, especially in high doses, was associated with an controversy, 4, 5 The present study by a British group 6 increased risk of myocardial infarction' (AMI) when is case control in design and contrasts with the procompared with the reference group which was the posal of Psaty et al 1 that CCAs are harmful when beta-blocker group. The major defects of this study compared with beta-blockers, so that both the include that: (1) in one-third of cases the pretreatreports warrant very careful examination. ment BP measurements were missing; (2) there were A number of major defects of case control studies confounding differences between the CCA and the are well known and include the following. First, beta-blocker group, such as the fact that more of the there is usually no guarantee that the subject had CCA group were diabetic; and (3) fatality rates were actually taken the drug or had used the right dosage.
not emphasized but were equal in the CCA and in It must also be assumed that there was no change of the beta-blocker groups. It follows that the increase medication during the period of the study, unless in AMI associated with CCAs was in non-fatal but there is effective follow-up which is unusual for a not in fatal infarctions. case control study. Second, there is no knowledge about the reason for choosing one drug rather than another, but it is reasonable to suppose that CCAs
The present study might have been preferred over diuretics for those Against that background, the study by Bulpitt et al 6 with pre-existing ischaemic heart disease. Thirdly, from the Royal Postgraduate Medical School in Lonconfounding factors are difficult to obviate. 7 For don is of considerable interest. First, the total numexample, if the perception is that diabetic patients ber of cases given CCAs is much larger (349 given should be given a CCA rather than a beta-blocker, CCAs in Britain vs 56 in the American study) also then there will be more diabetics, with their greater with many more given the combination of a CCA cardiovascular risk, in the CCA than in the betaplus a diuretic (643 vs 24, respectively). Second the blocker group, as happened in the study of Psaty et number given diuretics was also much larger, being al. average time that patients were studied was about 11 years in the British study and 7 years in the myself) especially in uncomplicated hypertensive patients. Diuretics are relatively safe and easy to use. American study. The most important difference is that the British study was sufficiently powered to
In several studies initial diuretic treatment with low dose, potassium-sparing agents has been used with give data on mortality in three categoriesischaemic heart disease (IHD), cardiovascular moroutcome benefit and reduction of mortality. 8, 11 In particular, potassium-sparing agents seem safer than tality and total mortality. The key results may be summarized as follows.
others on the evidence of case control studies. 9, 10 Potassium retainers maintain body potassium and Mortality due to IHD was non-significantly increased in all groups (methyldopa, CCA, betamagnesium better than non-retainers 12 and the consequence may be a decreased risk of serious carblocker and ACE inhibitor) when compared with a diuretic alone. Cardiovascular mortality was diac arrhythmias. The problem with singing the praises of diuretics on the basis of this British study increased only by methyldopa. Total mortality was increased by all three types of agents when comis that neither type nor dose of diuretic are known.
If the British doctors, in their wisdom, had chosen pared with diuretics, but only significantly so by methyldopa (adjusted for treated BP), or by CCAs predominantly low-dose potassium-sparing agents then this would explain why the beta-blockers in when adjusted for untreated BP, the latter being unavailable in 42% of the cases, whereas treated BP this study had a relative increase in mortality compared with the diuretic groups. levels were known in 73% of patients. Regarding the 'with diuretic groups', both IHD and cardiovascular
Other problems with the present study, are those common to all case control studies, including the mortality tended to be higher with CCAs, and were statistically higher with methyldopa. Total morfundamental fact that it will never be clearly known why a given drug or combination of drugs was tality, most surprisingly, was increased not decreased in three groups, specifically methyldopa chosen rather than another. It must also be assumed that the drugs were distributed to hypertensive plus diuretic, CCA plus diuretic and beta-blocker plus diuretic all with relative risks of 1.4 or slightly populations which were roughly comparable, to make up for the almost irreparable defect of nonmore. ACE inhibitors were excluded from this analysis because of low numbers. The authors conclude randomization. However, it is difficult to exclude the possibility that the diuretic group in the British that methyldopa, CCAs and beta-blockers were all associated with higher mortalities than the reference study were in fact those hypertensives who did not have associated end-organ damage, because, for diuretic groups, and that the results in the three nondiuretic groups were similar. It needs re-emphasis example, the diuretic group had a majority of females and the beta-blockers group a majority of that the selection bias cannot eliminate the possibility and indeed the probability ( Table 1) that males. Not enough data are available on various potential confounders such as diabetes. Nonethepatients with higher BP values were more likely to receive initial combination therapy with diuretics less, on the given data, the various groups seem to have comparative BP levels at entry, about 180/110 and another agent.
Allowing for these many serious defects, the Britmm Hg, except for beta-blockers without diuretics (about 170/105 mm Hg). BP levels during treatment ish study points the accusing finger not only at CCAs but also at beta-blockers and methyldopa. In fact, the were also comparable in all groups except that the values again seemed lowest in the beta-blocker results with methyldopa are so bad ( Table 2) that serious consideration might now be given to specific group. One interpretation could be that beta-blockers had the same dangers as other drugs but perhaps advice not to use this drug either on its own or in combination with a diuretic. An exception would evident despite lower BP levels. remain the short term use of methyldopa in pregnancy, where this drug has been studied better than Is there a case against beta-blockers in most others. A second exception is in the elderly, hypertension therapy? when monotherapy by a potassium-retaining diuretic has failed. 8 There is already evidence that Further evidence against beta-blockers for hypertension is as follows. There have been only two large beta-blockers, when compared with potassium-sparing diuretics, tend to cause sudden death 9,10 but the placebo controlled studies (RCTs) both conducted by the British Medical Research Council (MRC). In present data are the first to directly accuse betablockers when compared with diuretics. Further, the the first, on middle-aged subjects, the beta-blocker gave limited benefits in non-smokers and the fall in detrimental effect was especially noted when comparing a beta-blocker combined with diuretics alone mortality was slight and not significant. 13 In smoking men or women, propranolol did not reduce (relative risk, 1.57, CI 1.09-2.26). Regarding the CCAs, the authors have perhaps taken too lightly strokes, whereas the diuretic did. Again, in smokers, propranolol did not reduce coronary events (nor did their finding of an increased relative risk (RR) for total mortality with CCAs when adjusted for the diuretic). In non-smokers propranolol reduced stroke and coronary events in males but not in untreated rather than treated BP (Table 3 , right hand column), although in nearly 50% the untreated BP females. These results do not exactly show a dramatic benefit for propranolol, and certainly do not was not known which weakens this finding.
The consoling factor to emerge from this large argue strongly for a mortality benefit, because allcause mortality was low and unaffected by propranBritish study is that diuretic treatment seems least harmful. In general, diuretics are often chosen for olol. In the second trial, on patients aged 65-74, despite equal BP reduction by a diuretic and the first line treatment (and favoured by many including beta-blocker atenolol, 'the beta-blocker group sion, 18 and with increased mortality in the very elderly in one cohort study 2 and with acute ischaemic showed no significant reductions in these end points', which were stroke, coronary event and all syndromes in one meta-analysis. 3 In another metaanalysis reported to the FDA and yet to be pubcardiovascular events.
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Rather, there was an increased incidence of cardiovascular deaths in the lished, it was the short but not long acting form of nifedipine that was associated with adverse outbeta-blocker group (66 in diuretic and 95 in betablocker, P = 0.03), and a trend towards a greater comes. In summary, the present case control study suffers number of total deaths in the beta-blocker group (P = 0.07). There was a suggestion of increased cancer from the class defects of such studies, but the numbers are much larger than in previous reports and in the beta-blocker group. Overall, these results from placebo-controlled trials are hardly impressive for allow specific analysis of the incidence of deaths. The therapy seemingly safest was diuretics, in comthe beta-blocker and do not allow the conclusion that mortality was lessened. In comparative trials parison with which not only CCAs but also betablockers and especially methyldopa did badly. The with diuretics in middle-aged subjects, mortality was similar in the HAPPHY study 14 and lower in the numbers with ACE inhibitors are too small to allow comment. The adverse effects of the non-diuretic beta-blocker group in the MAPHY study 15 -the latter study evolved from the former and was in reality drugs could simply be explained by preferential choice of such drugs over diuretics for complicated a follow-up open-label study; it was not a simple prospective comparison. Of interest in the MAPHY hypertensives. Nonetheless, the disappointing data with the two adrenergic modifying drugs, betastudy, 15 the better result with the beta-blocker metoprolol was confined to smokers, in contradiction to blockers and methyldopa, are difficult to understand but may be related to intermittent adrenergic disthe MRC study, only the latter being placebocontrolled. Also relevant is that the comparator charge for a short-acting beta-blocker, 19 and to the well-described potentially fatal side effects of diuretic used in the MAPHY study 15 was a non-potassium retaining thiazide, which could have biased methyldopa such as severe haemolytic anaemia and liver failure. This report reinforces the view that eviresults towards the beta-blocker. 9 If the MAPHY study 15 is the only evidence there is for a benefit of dence-based medicine requires outcome data for the use of both CCAs (which are underway) and betabeta-blockers on mortality in hypertensives, then a modern view would have to be that the trial design blockers in hypertension. This report gives no support to the view that beta-blocking drugs beneficially was so faulted and the resultant evidence so weak, that it remains possible beta-blockers have no mormodify mortality in hypertensive patients, a view often ascribed to the authors of JNC V. Rather, outality benefit or even possible harm as suggested by the MRC study in the elderly and by the present case come data are seriously lacking. The often-quoted 'First do no harm' means that we should now be control study.
serious about collecting good prospective data for the real benefit in the treatment of hypertension not
Comparison with previous case control
only for CCAs and ACE inhibitors but also for studies beta-blockers. How do these results compare with other case control studies? It must be stated that each of the other Conclusion case report studies has a different end-point. For example, Psaty reported on non-fatal MI in patients
The present report, although suffering from the serimany of whom had other risk factors, the present ous defects inherent to case control studies, could study reports on deaths, the Jick study on AMI in suggest that diuretics are safer than CCAs, betahypertensives with no other risk factors, 16 and the blockers or methyldopa. The slow realization that Aursnes study on patients with AMI who did or did the case for data showing the long-term safety of not have hypertension. 17 Although the simplest both CCAs and beta-blockers when given for hyperwould be to group these studies together and to say tension is not immaculate, results from the new that taken together, the charge against CCAs is not critical eye which has been opened by controproven and the balance of evidence shows no large versy. 3, 20 scale adverse effects when compared to beta-block-'Controversy should be welcomed, it is only through ade, the mortality evidence from the present study controversy that science advances'.
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does point against both beta-blockers and CCAs when compared with diuretics. Geographic differences in patterns of drug use References may be important. The negative (for CCAs) case con- 
